SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Strong topline growth driven by solid performance across key brands.
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Subscribe To Our Newsletter & Stay Updated